Shares of drugmaker Teva (NYSE:TEVA) stumbled in 2013, finishing the year far behind the S&P 500.
Today, however, this stock trades at an attractive multiple and could be set for a rebound in 2014. But is it smooth sailing ahead for this unique drugmaker, or are there challenges in the coming years that should worry investors? Analyst Max Macaluso explores this stock in the following video and presents one reason to avoid Teva and one reason to be optimistic about the stock's future.
Editor's Note: At 2:37, Max meant to say Teva appointed "Erez Vigodman."
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.